Prognostic factors and effectiveness of the first-line therapy for chronic lymphocytic leukemia: results of 10-year follow-up

Učenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta im. Akad. I.P. Pavlova

I. M. Barhatov¹  N. B. Mikhailova¹  N. P. Volkov¹  О. B. Kalashnikova¹  E. V. Kondakova¹  T. L. Gindina¹  E. V. Babenko¹  I. S. Moiseev¹  A. D. Kulagin¹  M. O. Ivanova¹  E. A. Izmailova¹ 

[1] Pavlov University;

关键词: chronic lymphocytic leukemia;    prognostic markers;    predictors of the response;    ighv mutation status;    del17p;    complex karyotype;   

DOI  :  10.24884/1607-4181-2020-27-3-80-96

来源: DOAJ

【 摘 要 】

Introduction.The biological heterogeneity of chronic lymphocytic leukemia (CLL) is reflected in the rate of progression, the need for therapy, and the response to treatment. Analysis of prognostic factors contributes to improving the quality of treatment and rational distribution of healthcare resources.Materials and methods. Among 890 patients with documented stage of CLL, 405 (45.5 %) received treatment. As the first-line of treatment, 173 patients received intensive regimens (FCR or BR), 6 – new agents, and 226 – all other regimens. The initial stage of the disease, mutation status of IGHV, del17p with or without complex karyotype were analyzed as prognostic markers.Results. Immunochemotherapeutic regimens were shown to be highly effective in case planned amount of treatment was completed. The combination of such prognostic parameters as the initial stage of the disease, the mutation status of IGHV, and the presence of del17p and/or complex karyotype allows us to clearly identify a group of patients with an unfavorable prognosis, for which it is advisable to use either intensive programs or new agents in the first-line therapy.

【 授权许可】

Unknown